KR102512777B1 - 안구 장애의 치료 방법 - Google Patents

안구 장애의 치료 방법 Download PDF

Info

Publication number
KR102512777B1
KR102512777B1 KR1020237000103A KR20237000103A KR102512777B1 KR 102512777 B1 KR102512777 B1 KR 102512777B1 KR 1020237000103 A KR1020237000103 A KR 1020237000103A KR 20237000103 A KR20237000103 A KR 20237000103A KR 102512777 B1 KR102512777 B1 KR 102512777B1
Authority
KR
South Korea
Prior art keywords
formula
compound
iiia
iiib
administered
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020237000103A
Other languages
English (en)
Korean (ko)
Other versions
KR20230010813A (ko
Inventor
더글라스 마이클 주니어 애커만
제임스 로우딘
케네스 제이. 만델
Original Assignee
오이스터 포인트 파마 인코포레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 오이스터 포인트 파마 인코포레이티드 filed Critical 오이스터 포인트 파마 인코포레이티드
Publication of KR20230010813A publication Critical patent/KR20230010813A/ko
Application granted granted Critical
Publication of KR102512777B1 publication Critical patent/KR102512777B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A61K38/13—Cyclosporins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/04—Artificial tears; Irrigation solutions

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Ophthalmology & Optometry (AREA)
  • Otolaryngology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
KR1020237000103A 2016-04-07 2017-04-06 안구 장애의 치료 방법 Active KR102512777B1 (ko)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201662319648P 2016-04-07 2016-04-07
US62/319,648 2016-04-07
KR1020187032218A KR102485299B1 (ko) 2016-04-07 2017-04-06 안구 장애의 치료 방법
PCT/US2017/026385 WO2017177024A1 (en) 2016-04-07 2017-04-06 Methods of treating ocular conditions

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
KR1020187032218A Division KR102485299B1 (ko) 2016-04-07 2017-04-06 안구 장애의 치료 방법

Publications (2)

Publication Number Publication Date
KR20230010813A KR20230010813A (ko) 2023-01-19
KR102512777B1 true KR102512777B1 (ko) 2023-03-23

Family

ID=58549326

Family Applications (2)

Application Number Title Priority Date Filing Date
KR1020187032218A Active KR102485299B1 (ko) 2016-04-07 2017-04-06 안구 장애의 치료 방법
KR1020237000103A Active KR102512777B1 (ko) 2016-04-07 2017-04-06 안구 장애의 치료 방법

Family Applications Before (1)

Application Number Title Priority Date Filing Date
KR1020187032218A Active KR102485299B1 (ko) 2016-04-07 2017-04-06 안구 장애의 치료 방법

Country Status (19)

Country Link
US (3) US10709707B2 (enExample)
EP (2) EP3970724A1 (enExample)
JP (3) JP7090551B2 (enExample)
KR (2) KR102485299B1 (enExample)
CN (3) CN114533737B (enExample)
AU (1) AU2017248276B2 (enExample)
DK (1) DK3439661T3 (enExample)
EA (1) EA201892265A1 (enExample)
ES (1) ES2893126T3 (enExample)
IL (3) IL299204A (enExample)
MX (2) MX385698B (enExample)
MY (1) MY199237A (enExample)
NZ (1) NZ746468A (enExample)
PH (1) PH12018502154A1 (enExample)
PT (1) PT3439661T (enExample)
SG (1) SG11201808650QA (enExample)
TW (2) TWI790997B (enExample)
WO (1) WO2017177024A1 (enExample)
ZA (1) ZA201807438B (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9145396B2 (en) 2008-12-01 2015-09-29 Targacept, Inc. Synthesis and novel salt forms of (R)-5-((E)-2-pyrrolidin-3ylvinyl)pyrimidine
PT3848028T (pt) 2014-10-20 2024-09-20 Oyster Point Pharma Inc Métodos de tratamento de estados oculares
PT3439661T (pt) 2016-04-07 2021-09-30 Oyster Point Pharma Inc Métodos de tratamento de condições oculares
WO2020014217A1 (en) 2018-07-10 2020-01-16 Oyster Point Pharma, Inc. Methods of treating ocular conditions
EP3820443A1 (en) 2018-07-10 2021-05-19 Oyster Point Pharma, Inc. Combinations of positive allosteric modulators and nicotinic acetylcholine receptor agonists for treating ocular conditions
WO2021222230A1 (en) * 2020-04-28 2021-11-04 Oyster Point Pharma, Inc. Local administration of nicotinic acetylcholine receptor agonists for the inhibition of coronavirus infections
JP2024517459A (ja) * 2021-05-07 2024-04-22 オイスター ポイント ファーマ インコーポレイテッド ベクター及びニコチン作動薬の併用療法

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010065443A1 (en) 2008-12-01 2010-06-10 Targacept, Inc. Synthesis and novel salt forms of (r)-5-((e)-2-(pyrrolidin-3-ylvinyl)pyrimidine

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6277855B1 (en) * 2000-04-21 2001-08-21 Inspire Pharmaceuticals, Inc. Method of treating dry eye disease with nicotinic acetylcholine receptor agonists
US20030008892A1 (en) 2001-07-09 2003-01-09 Pfizer Inc. Pharmaceutical composition and method of modulating cholinergic function in a mammal
EP1461040B1 (en) 2001-11-29 2006-03-15 Pfizer Products Inc. Succinic acid salts of 5,8,14-triazatetracyclo[10.3.1.0 2,11 .0 4,9 ]-hexadeca-2(11),3,5,7,9,-pentaene and pharmaceutical compositions thereof
AU2003269413A1 (en) 2002-11-01 2004-05-25 Pharmacia & Upjohn Company Llc Nicotinic acetylcholine agonists in the treatment of glaucoma and retinal neuropathy
US7098331B2 (en) 2003-03-05 2006-08-29 Targacept, Inc. Arylvinylazacycloalkane compounds and methods of preparation and use thereof
US20060270592A1 (en) 2004-03-19 2006-11-30 Ophthalmic Research Associates, Inc. Use of neurotransmitters and neuropeptides for the treatment of dry eye diseases and related conditions
CA2583101A1 (en) 2004-10-15 2006-04-20 Pfizer Products Inc. Compositions and methods for intranasal, buccal, sublingual and pulmonary delivery of varenicline
US20090023819A1 (en) 2005-03-22 2009-01-22 Anders Axelsson Use of an Artificial Sweetener to Enhance Absorption of Nicotine
US20110086086A1 (en) 2005-07-26 2011-04-14 Pfizer Inc Transdermal system for varenicline
TWI404532B (zh) 2006-11-02 2013-08-11 Targacept Inc 菸鹼乙醯膽鹼受體亞型選擇性之二氮雜雙環烷類醯胺
ES2368286T3 (es) 2007-02-02 2011-11-16 Pfizer Products Inc. Compuestos tricíclicos y su uso como moduladores de los receptores de glucocorticoides.
WO2008157365A2 (en) * 2007-06-15 2008-12-24 Targacept, Inc. Vinylazacycloalkanes for treating neuropathic pain
US20090093446A1 (en) 2007-10-05 2009-04-09 Winston Laboratories, Inc. Method for alleviating keratoconjunctivitis sicca
CL2008003507A1 (es) 2007-11-26 2009-11-27 Neuroderm Ltd Composicion farmaceutica que comprende nicotina y un inhibidor de la desensibilizacion del receptor de acetilcolina nicotinico (nachr) opipramol; kit farmaceutico; dispositivo medico; y uso para tratar una enfermedad o trastorno del sistema nervioso central o periferico.
AU2009221860A1 (en) 2008-03-05 2009-09-11 Targacept, Inc. Nicotinic acetylcholine receptor sub-type selective amides of diazabicycloal kanes
CN102143963A (zh) 2008-09-05 2011-08-03 塔加西普特公司 二氮杂双环辛烷的酰胺及其应用
WO2010028011A1 (en) 2008-09-05 2010-03-11 Targacept, Inc. Amides of diazabicyclononanes and uses thereof
MX2011003306A (es) * 2008-10-14 2011-09-01 Psychogenics Inc Ligandos nicotinicos de receptor de acetilcolina y los usos de los mismos.
US9145396B2 (en) * 2008-12-01 2015-09-29 Targacept, Inc. Synthesis and novel salt forms of (R)-5-((E)-2-pyrrolidin-3ylvinyl)pyrimidine
TW201024283A (en) 2008-12-01 2010-07-01 Targacept Inc Synthesis and novel salt forms of (R)-3-((E)-2-(pyrrolidin-3-yl)vinyl)-5-(tetrahydropyran-4-yloxy)pyridine
JP2012530707A (ja) * 2009-06-17 2012-12-06 ターガセプト，インコーポレイテッド 神経性ニコチン受容体リガンドによるｌ−ドーパ誘発性ジスキネジアの回復
US20110274628A1 (en) 2010-05-07 2011-11-10 Borschke August J Nicotine-containing pharmaceutical compositions
US8821457B2 (en) 2010-09-08 2014-09-02 Johnson & Johnson Vision Care, Inc. Punctal plug containing drug formulation
CA3083244C (en) 2011-10-20 2023-01-03 Novartis Ag Biomarkers predictive of responsiveness to alpha 7 nicotinic acetylcholine receptor activator treatment
CN104094114A (zh) 2011-11-30 2014-10-08 黛尔格诺斯蒂尔有限公司 干眼诊断
PT3848028T (pt) 2014-10-20 2024-09-20 Oyster Point Pharma Inc Métodos de tratamento de estados oculares
PT3439661T (pt) * 2016-04-07 2021-09-30 Oyster Point Pharma Inc Métodos de tratamento de condições oculares

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010065443A1 (en) 2008-12-01 2010-06-10 Targacept, Inc. Synthesis and novel salt forms of (r)-5-((e)-2-(pyrrolidin-3-ylvinyl)pyrimidine

Also Published As

Publication number Publication date
SG11201808650QA (en) 2018-10-30
WO2017177024A1 (en) 2017-10-12
DK3439661T3 (da) 2021-10-18
MY199237A (en) 2023-10-22
JP2022120125A (ja) 2022-08-17
KR20230010813A (ko) 2023-01-19
WO2017177024A8 (en) 2018-11-08
CA3020170A1 (en) 2017-10-12
ES2893126T3 (es) 2022-02-08
MX385698B (es) 2025-03-18
EP3439661A1 (en) 2019-02-13
IL262102A (en) 2018-11-29
EA201892265A1 (ru) 2019-04-30
TW202320785A (zh) 2023-06-01
MX2018012230A (es) 2019-03-28
NZ746468A (en) 2023-06-30
BR112018070497A2 (pt) 2019-01-29
IL290069B1 (en) 2023-01-01
KR20190005859A (ko) 2019-01-16
US20200345734A1 (en) 2020-11-05
CN109310692A (zh) 2019-02-05
PT3439661T (pt) 2021-09-30
MX2021010399A (es) 2022-01-18
NZ785093A (en) 2024-07-05
CN114533737B (zh) 2024-05-31
US20250000861A1 (en) 2025-01-02
TWI876258B (zh) 2025-03-11
AU2017248276B2 (en) 2023-07-13
AU2017248276A1 (en) 2018-11-22
JP7090551B2 (ja) 2022-06-24
TWI790997B (zh) 2023-02-01
CN109310692B (zh) 2022-01-25
PH12018502154A1 (en) 2019-07-08
US10709707B2 (en) 2020-07-14
KR102485299B1 (ko) 2023-01-06
IL262102B (en) 2022-03-01
CN114432313A (zh) 2022-05-06
IL290069B2 (en) 2023-05-01
IL299204A (en) 2023-02-01
EP3439661B1 (en) 2021-08-04
TW201737917A (zh) 2017-11-01
EP3970724A1 (en) 2022-03-23
ES2893126T8 (es) 2022-05-23
IL290069A (en) 2022-03-01
JP2024103594A (ja) 2024-08-01
US20190201397A1 (en) 2019-07-04
CN114533737A (zh) 2022-05-27
ZA201807438B (en) 2024-09-25
JP2019513759A (ja) 2019-05-30

Similar Documents

Publication Publication Date Title
KR102512777B1 (ko) 안구 장애의 치료 방법
US20250255865A1 (en) Methods of treating ocular conditions
HK40063370A (en) Methods of treating ocular conditions
HK40004067B (en) Methods of treating ocular conditions
BR112018070497B1 (pt) Métodos e formulações farmacêuticas para tratamento de condições oculares
EA047371B1 (ru) Применение соединения при лечении сухости глаз или дискомфорта в глазах
EA040442B1 (ru) Применение соединения при лечении сухости глаз или дискомфорта в глазах
CA3020170C (en) Methods of treating ocular conditions
HK40035962A (en) Methods of treating ocular conditions
HK40035961A (en) Methods for treating eye disease

Legal Events

Date Code Title Description
A107 Divisional application of patent
PA0104 Divisional application for international application

St.27 status event code: A-0-1-A10-A16-div-PA0104

St.27 status event code: A-0-1-A10-A18-div-PA0104

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

Fee payment year number: 1

St.27 status event code: A-2-2-U10-U12-oth-PR1002

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000